A policy update described by BioCentury says the FDA is moving from a punitive approach to a reward-based “America First” framework under PDUFA. The reauthorization is framed as reducing fees by $2 million for first-in-human (FIH) trials conducted domestically, contrasted with prior arrangements that included an estimated $10 million penalty for conducting FIH studies overseas. The reported shift would reweight economic incentives in drug development, potentially affecting sponsor decisions on trial geographies and the composition of early clinical study plans. It also signals how regulatory performance and funding mechanisms are being used to steer industrial behavior. For biotech operators running early-stage programs, any modification to FIH incentives can change both planning and budgeting assumptions at the moment clinical execution and investigator selection are already high-risk.